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The activity and toxicity profile of gefitinib in non-small cell lung cancer (NSCLC) patients aged 70 years or older has been only
partially evaluated. The aim of this study was to evaluate the response rate and safety of gefitinib in elderly NSCLC patients. Elderly
NSCLC patients pretreated with chemotherapy and with at least one measurable lesion received gefitinib at the daily dose of 250mg
until disease progression, unacceptable toxicity or refusal. From August 2001 to May 2003, 40 consecutive elderly patients have been
enrolled onto the study in three Italian institutions. We observed one complete (2.5%) and one partial response (2.5%), 18 disease
stabilisations (NC: 45%) lasting at least 2 months, including six patients (15%) who had disease stabilisation of 6 months or longer, for
an overall disease control rate of 50% (95% CI: 34.5–65.5%). The median duration of response was 4.4 months (range 1.7–9.2). The
side effects were generally mild and consisted of diarrhoea and skin toxicity. Grade 1–2 diarrhoea occurred in 23.6%, and one patient
experienced grade 4 diarrhoea, requiring hospitalisation. Grade 1–2 skin toxicity, including rash, pruritus, dry skin, and acne, occurred
in 20 patients (52.6%). Gefitinib is safe and well tolerated in elderly pretreated NSCLC patients. The disease-control rate achieved
suggests that this drug could represent a valid option in the management of this unfavourable subgroup of patients.
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Non-small-cell lung cancer (NSCLC) is the most lethal malignant
tumour in the United States with an estimated 169500 new patients
diagnosed and 157400 deaths in 2001. Approximately 30% of those
diagnosed are patients aged 70 years or older (Hutchins et al, 1999;
Greenlee et al, 2001). Treatment of elderly NSCLC patients
represents a challenge in clinical practice, because these patients
are not eligible for aggressive therapies due to the age-related
reduction of the functional reserve of many organs and
comorbidities (Balducci et al, 2000). Recent data suggest that
platinum-based chemotherapy can be safely proposed to the
elderly (Langer et al, 2002), but so far mainly single-agent
chemotherapy with vinorelbine or gemcitabine has been consid-
ered as the standard treatment for advanced disease (Gridelli et al,
2003). Although elderly patients have not been excluded from
randomised phase III trials evaluating the activity of second-line
chemotherapy (Shepherd et al, 2000; Hanna et al, 2003), only very
selected patients with good performance status are candidates to
salvage chemotherapy in everyday clinical practice.
Since its identification, the epidermal growth factor receptor
(EGFR) has emerged as a significant factor in the development and
growth of many types of cancers. It is now accepted that the EGFR
signal transduction network plays an important role in multiple
tumorigenic processes, contributing to cancer-cell proliferation,
angiogenesis, and metastasis, as well as protection from apoptosis
(Huang and Harari, 1999). Since the majority of NSCLC expresses
EGFR, this represents a rational target for novel agents that can
block cancer cell growth by interfering with this mitogenic
signalling pathway. Gefitinib (ZD1839, IRESSA, Astrazeneca,
London, UK) is an orally active, selective EGFR tyrosine-kinase
inhibitor (TKI) that blocks signal transduction pathways impli-
cated in the proliferation and survival of cancer cells (Rusch et al,
1993; Salomon et al, 1995). The 11% response rate observed in
phase I trials (Kris et al, 2000) led to two large phase II studies
evaluating the activity and tolerability of two different gefitinib
doses. In the first trial (IDEAL 1), 210 pretreated NSCLC patients
were randomised to ZD 1839 250 or 500mg daily dose (Fukuoka
et al, 2003). This trial showed an 18% response rate with
symptomatic improvement in 40% of patients, without any
significant difference between the two dose levels. In the US trial
(IDEAL 2), 216 NSCLC patients, who had failed in two or more
prior chemotherapy regimens containing platinum and docetaxel,
were randomly assigned to ZD 1839 250 or 500mg daily. This trial
confirmed that ZD 1839 is active in heavily pretreated NSCLC
patients, with a response rate of 11.8% and symptom improvement
in 43% of patients in the 250mg arm (Kris et al, 2000). Although
the age of 70 years or older was not considered as an exclusion
criteria, in all these studies, the safety and activity of gefitinib in
the elderly population has not been directly addressed. At the daily
dose of 250mg, skin toxicity and diarrhoea are the main gefitinib
side effects, occurring in 46.6 and 39.8% of cases, respectively
(Fukuoka et al, 2003). In the elderly, the risk of diarrhoea is of
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lparticular importance due to dehydration and electrolyte imbal-
ance that can even be life threatening. Moreover, although gefitinib
is considered a very well-tolerated drug, recent findings suggest
that in some patients (1–2% in Japan) gefitinib has the potential of
causing acute interstitial pneumonia, and this side effect is more
common in patients with comorbidities or those who received
previous mediastinal radiotherapy (Inoue et al, 2003). Based on
these considerations, we decided to assess the safety and activity of
gefitinib in pretreated elderly patients with advanced NSCLC. To
conduct this trial, we used gefitinib provided by Astrazeneca
within the expanded access program.
PATIENTS AND METHODS
Patient selection
The eligibility criteria were: histologic or cytologic confirmation of
locally advanced or metastatic NSCLC; stage III or stage IV disease
not amenable to surgery or radiotherapy at the study entry;
recurrent or refractory disease following at least one previous
chemotherapy regimen; evidence of disease progression at the time
of study entry; at least one bidimensionally measurable or
radiographically assessable lesion; age of 70 years or older; ECOG
performance status (PS) of 0–2; life expectancy of at least 12
weeks; and white blood cell count Z3.5 10
91
 l, platelets
Z100 10
91
 l, haemoglobin Z9gdl
 1, and absolute granulocyte
count (AGC) 42.0 10
91
 l; bilirubin o1.5-fold the upper limit
of normal (ULN). Evaluation of creatinine level was not required
for trial inclusion. Patients with stable brain metastases were
eligible. Written informed consent was obtained from each patient
before entering the study. The study was conducted after the
approval of the appropriate ethical review boards. Recommenda-
tions of the Declaration of Helsinki for biomedical research
involving human subjects were also followed.
Study design and treatment
In this study, consecutive elderly NSCLC patients received gefitinib
at the daily dose of 250mg given until disease progression,
unacceptable toxicity or refusal. Baseline evaluation included a
complete history and physical examination, a complete blood cell
count and serum chemistry analysis, urinalysis, an ECG, chest X-
ray, and a total body computed tomography scan. Other imaging
modalities, such as magnetic resonance imaging and bone
scintigraphy, were performed according to specific clinical
indications. All baseline imaging procedures were performed
within 4 weeks before the study entry. After trial inclusion, toxicity
and disease-related symptom assessment were performed every 28
days. Toxic effects were assessed according to the NCI CTC
(Common toxicity criteria: National Institute of Health, Cancer
Therapy Evaluation Program, Division of Cancer Treatment, 1993).
Symptom assessment was carried out by the physician, and no
questionnaire was used. The side effects and safety were evaluated
clinically and through the assessment of serum creatinine,
electrolytes, alkaline phosphatase, bilirubin, AST, ALT, calcium,
magnesium, and protein levels. Chest X-ray was repeated after 1
month of gefitinib therapy and thereafter in the case of lung
disease suspicion. Patients were evaluated for response according
to the RECIST Criteria (Therasse, 2000). Tumour response was
assessed by computer tomography (CT) scan every 2 months, with
a confirmatory evaluation to be repeated in the responding
patients at least 4 weeks after the initial determination of response.
Statistical considerations
The number of 40 patients to enroll onto the study was calculated
according to the method by Gehan (1961). This was to ensure that
the drug had a less than 20% disease control rate, and that the
study could be terminated with a maximal error of 5% in
estimation of the true response rate. Every patient included in the
trial has been considered evaluable (intent to treat analysis). Stable
disease was measured from the start of the treatment until the
criteria for disease progression was met. The duration of overall
response was measured from the time that criteria were met for
complete response or partial response, until the first date that
recurrent or progressive disease was documented.
RESULTS
Patient characteristics
From August 2001 to May 2003, 40 consecutive elderly patients
were treated with a daily dose of 250mg of ZD 1839 in three Italian
institutions. Of these, 40 patients were evaluable for efficacy, and
38 patients were evaluable for safety. In two cases, safety data were
not recorded on the patient file. Characteristics of the eligible
patients are listed in Table 1. The majority of patients were male
(82.5%), with a median age of 74 years (range 70–88), and with an
Table 1 Patient characteristics
Total enrolled: 40 N %
Sex
Male 33 82.5
Female 7 17.5
Age (year)
Median 74
Range 70–88
Stage
IIIB 11 27.5
IV 29 72.5
Histology
Squamous cell carcinoma 14 35
Adenocarcinoma 18 45
Bronchiolar–alveolar carcinoma 4 10
Undifferentiated NSCLC 4 10
Site of metastases
Lung 23
Liver 3
Bone 7
Brain 2
Pleura 4
Adrenal 2
Skin 2
Number of metastatic sites
0 11 27.5
1 19 47.5
26 1 5
3+ 4 10
ECOG performance status
01 0 2 5
1 27 67.5
2 3 7.5
Symptoms at study entry 20 50
Previous chemotherapy lines
1 21 52.5
21 6 4 0
3+ 3 7.5
Pretreated with platinum 19 47.5
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lECOG PS of 0, 1, and 2 in 10, 27, and 3 patients, respectively.
Histology was adenocarcinoma in 45%, bronchiolar–alveolar in
10%, squamous-cell carcinoma in 35%, and undifferentiated
carcinoma in 10% of cases. Lung represented the main metastatic
site (23 cases), and two patients had brain metastases. The
majority of patients had only one metastatic site (47.5%), and only
10% of patients had three or more organs involved by the disease.
All patients have been pretreated with chemotherapy. In all, 19
patients (47.5%) received platinum-based chemotherapy, while 21
patients were treated with non-platinum compounds. A total of 21
patients (52.5%) received gefitinib as second-line therapy, and only
three patients (7.5%) received the experimental drug after the
failure of three chemotherapy lines. At study entry, 29 patients
(72.5%) were stage IV, and 11 (27.5%) were stage III, including
three patients with pleural effusion. Four patients with stage III
disease and without pleural effusion had been pretreated with
mediastinal radiotherapy completed at least 4 months before study
entry, and all had evidence of disease progression. In total, 28
patients were current smokers, seven former smokers, and five no
smokers. The most frequent comorbidity was cardiovascular,
occurring in 28 patients (70%). The vast majority of patients were
on treatment for hypertension (57%), or had a history of coronary
artery disease or stroke (25%). Respiratory symptoms were
reported in eight patients (20%), mainly because of chronic
obstructive pulmonary disease. Although specific renal diseases
were not reported, 10 patients (25%) presented elevated creatinine
levels at study entry (Table 2).
Response to therapy
Among the 40 patients enrolled, we observed one complete (CR:
2.5%) and one partial response (PR: 2.5%), for an overall response
rate of 5%. A total of 18 patients (45%) had disease stabilisation
lasting at least 2 months, including six patients (15%) who had a
disease stabilisation of 6 months or longer, for an overall disease-
control rate of 50% (95% CI: 34.5–65.5%). No difference in
response rate was observed in platinum-naı ¨ve vs platinum-
pretreated patients. Partial response was observed in a patient
previously treated with platinum-based chemotherapy. Complete
response was observed in an 83-year-old platinum-naı ¨ve patient,
who experienced grade 3 skin toxicity that caused temporary
therapy withdrawal. In this patient, CT scan performed after 3
months of gefitinib therapy showed PR, while the CT scan
performed after 10 months of therapy demonstrated complete
disappearance of the disease. The median duration of response was
4.4 months (range 1.7–9.2). So far, 25 patients are still alive and
eight patients are on treatment, including the two responding
patients (6.6þ and 7þ months). The median time to progression
and overall survival time were 3 and 5 months, respectively.
Toxicity and symptom outcome
The side effects were generally mild and consisted of diarrhoea and
skin toxicity. Grade 1–2 diarrhoea occurred in nine patients
(23.6%), and one patient experienced grade 4 diarrhoea, requiring
hospitalisation. This patient refused to continue therapy, despite
radiological evidence of disease stabilisation. In all the other
patients, diarrhoea resolved while on treatment, without dose
reduction or suspension. Grade 1–2 skin disorders, including rash,
pruritus, dry skin, and acne, occurred in 20 patients (52.6%). In
these patients, skin toxicity did not require any change of therapy.
Two patients experienced grade 3 skin toxicity. In these patients,
this side effect required temporary drug discontinuation. No one
experienced interstitial lung disease-type event during the study.
Patients had no deterioration in hepatic function, and no clinically
significant deterioration in renal function was observed during the
trial, even in patients who entered the trial with mild or moderate
renal impairment. No clinically significant changes in haematolo-
gic parameters were observed during the trial; most patients
experienced no changes from baseline in CTC grade for
haemoglobin, platelets, or WBC values. Grade 1 or 2 drug-related
ophthalmic side effects not requiring any therapy modification
were observed in seven patients (18.4%). At study entry, 20
patients presented disease-related symptoms mainly consisting of
dyspnea (17.5%) and asthenia (15%). After 1 month of gefitinib
therapy, disease-related symptoms improved in 35%, remained
stable in 25%, and got worse in 40% of cases (Table 3).
Symptomatic improvement occurred in five patients experiencing
disease stabilisation, and also in two patients with progressive
disease.
DISCUSSION
This study shows that gefitinib, at the daily dose of 250mg, can be
safely administered in elderly NSCLC patients. The overall
response rate was 5, and 45% of patients had disease stabilisation.
All patients had advanced NSCLC relapsing or progressing after
first-line chemotherapy. At the present time, the only FDA-
approved drug for second-line therapy is docetaxel, with a
response rate of almost 6% in randomised phase III trials (Fossella
et al, 2000; Shepherd et al, 2000). Although elderly patients have
not been excluded from second-line chemotherapy trials (Shep-
herd et al, 2000; Hanna et al, 2003), in clinical practice, a second
option is generally offered only to well-selected cases, with good
Table 2 Baseline comorbidities
N %
Total patients 40 100
N comorbidity
01 2
11 0
28
421 0
Type
Cardiovascular 39
Respiratory 8
Neurologic 2
Diabetes 3
Urinary 5
Creatinine level
Median value (mgdl
 1) 1.04
Range (mgdl
 1) 0.59–2.72
o1.2mgdl
 1 23
41.2mgdl
 1 10
Not available 7
Table 3 Symptom outcome
Baseline symptoms N (%)
Outcome after 1 month
Better (%) Stable (%) Worse (%)
Total patients 40 (100) 17.5 42.5 40.0
Total with symptoms 20 (50) 35.0 25.0 40.0
Dyspnea 7 (17.5) 28.6 28.6 42.8
Asthenia 6 (15.0) 16.7 50.0 33.3
Emoftoe 2 (5.0) 100 0 0
Bone pain 5 (12.5) 20.0 20.0 60.0
Cough 2 (5.0) 100 0 0
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lperformance status and without significant comorbidities. Gefiti-
nib is a TKI that was demonstrated to be active in pretreated
NSCLC patients (Kris et al, 2000). The activity and tolerability of
gefitinib as a single agent has been evaluated in two large phase II
studies (Kris et al, 2000; Fukuoka et al, 2003), and also in smaller
studies with unselected pretreated NSCLC patients enrolled in the
ZD1839 Expanded Access Programme (Janne et al, 2002;
Ruckdeschel et al, 2002; Argiris et al, 2003; Kommareddy et al,
2003; Pallis et al, 2003). All these trials showed that gefitinib is a
valid option for pretreated NSCLC patients, with response rates
ranging from 5 to 18%, and with a consistent portion of patients
experiencing disease stabilisation. Although elderly patients were
also enrolled in all these trials, the activity of gefitinib in this
subgroup has not been addressed. The response rate (CR þPR)
observed in our trial was only 5%, lesser than that reported in the
IDEAL 1 and 2 trials, but not different from that reported in other
compassionate use studies (Janne et al, 2002; Ruckdeschel et al,
2002; Argiris et al, 2003; Copin et al, 2003; Kommareddy et al,
2003; Pallis et al, 2003). Moreover, in our study, disease
stabilisation has been documented in 45% of patients, and,
importantly, 15% had disease stabilisation lasting at least 6
months. This finding is interesting because prolonged disease
stabilisation has been obtained in patients with evidence of
progressive disease when gefitinib therapy was started. These data
suggest that disease stabilisation has been caused by the drug and
it is not related to the natural history of a slow-growing tumour.
The rate of disease control was comparable to that obtained in the
IDEAL 1 trial, in which it was 54.4% (Kris et al, 2002). With respect
to safety, therapy was well tolerated and side effects were mild,
consisting mainly of diarrhoea and skin reactions. Before starting
the study, we were weary about the risk of inducing diarrhoea in
this particular group of patients. The overall incidence of
diarrhoea was 26.2%, and it was generally mild. Only two patients
had grade 2 diarrhoea, requiring loperamide treatment. The only
patient who experienced grade 4 diarrhoea was hospitalised,
discontinued the drug, and received rehydration therapy plus
loperamide, with disappearance of symptoms in 1 day. Skin
toxicity occurred in 67.8% of cases and did not require any specific
therapy. Only patients with grade 2 skin toxicity associated with
pruritus required systemic administration of steroids and/or
antihistaminics, with benefit and no drug suspension. In the two
patients who experienced grade 3 skin toxicity, steroids and
antihistaminics were ineffective and therapy was temporarily
discontinued. Monitoring of renal and hepatic function did not
reveal any abnormality. The risk of lung toxicity, such as
interstitial lung-disease-type events, has been evaluated by chest
X-ray performed after 1 month of gefitinib therapy, and also in all
cases of worsening or new-onset dyspnea. No patient experienced
lung toxicity, and, in the three patients in whom there was
worsening dyspnea, this was mainly due to disease progression.
The side effects reported in our study are similar to those reported
in other trials in which diarrhoea and skin toxicity occurred in
about 40 and 50% of cases (Janne et al, 2002; Ruckdeschel et al,
2002; Argiris et al, 2003; Copin et al, 2003; Fukuoka et al, 2003;
Kommareddy et al, 2003; Pallis et al, 2003). Symptom assessment
was not the main end point of our study, and for that reason no
questionnaire has been used. Symptoms were evaluated carefully
by the physician at each visit, and symptomatic improvement was
observed in 35% of patients after 1 month of gefitinib therapy,
mainly in those responding to gefitinib therapy, but also in two
nonresponding patients. Although a comparison is not possible
due to the different evaluation method, our results are similar to
those achieved in the IDEAL 1 study, in which symptomatic
improvement occurred in 40.3% of patients treated with the
250mg gefitinib daily dose. In conclusion, this study suggests that
gefitinib is safe and well tolerated in elderly pretreated NSCLC
patients. Although the response rate is not impressive, the disease-
control rate achieved leads to the conclusion that this drug could
represent a valid option in the management of this unfavourable
subgroup of patients. Further studies comparing gefitinib with
chemotherapy or with best supportive care are needed to better
define the role of this compound in the elderly.
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